(HealthDay News) — For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION), according ...

New research has revealed factors associated with an increased risk of COVID-19-related death and hospitalization among patients with cancer.

(HealthDay News) — Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c (HbA1c) for children and adolescents with type 2 diabetes mellitus (T2DM), according to a study ...

No significant increases seen in rate of hospital contacts for any of 29 adverse events in 28-day risk period after vaccination.

(HealthDay News) — Cardiovascular risk factor and disease mortality varies significantly among Asian Indian, Chinese, and Filipino Americans, with Filipino Americans having the highest mortality ...

Pemivibart was well tolerated and prophylactic against COVID-19 infection among adult patients with significant immunocompromising conditions.

In solid organ transplant recipients (SOTRs) with advanced cancer treated with immune checkpoint inhibitors (ICIs), cancer outcomes and transplant rejection risk vary by cancer type, investigators ...

A phase 2 trial tested the efficacy and safety of potravitug, an investigational monoclonal antibody, in kidney transplant recipients with BK polyomavirus DNAemia.

Among patients with NMIBC, BCG treatment may be less effective for patients with a history of UTUC, suggesting they are at greater risk for progression.

(HealthDay News) — Having a supratherapeutic international normalized ratio (INR) while taking warfarin does not significantly increase the risk for brain bleeding after blunt head trauma in older ...

A US population-based study comprehensively evaluated the relationship between chronic kidney disease (CKD) stage and angiodysplasia-related gastrointestinal bleeding.

Less than one-quarter of next-in-class cancer drugs demonstrated a survival benefit over existing in-class agents in head-to-head trials.